286 related articles for article (PubMed ID: 30336824)
1. Effect of Evolocumab on Coronary Plaque Composition.
Nicholls SJ; Puri R; Anderson T; Ballantyne CM; Cho L; Kastelein JJP; Koenig W; Somaratne R; Kassahun H; Yang J; Wasserman SM; Honda S; Shishikura D; Scherer DJ; Borgman M; Brennan DM; Wolski K; Nissen SE
J Am Coll Cardiol; 2018 Oct; 72(17):2012-2021. PubMed ID: 30336824
[TBL] [Abstract][Full Text] [Related]
2. Effect of combining evolocumab with statin on carotid intraplaque neovascularization in patients with premature coronary artery disease (EPOCH).
Han Y; Ren L; Fei X; Wang J; Chen T; Guo J; Wang Q
Atherosclerosis; 2024 Apr; 391():117471. PubMed ID: 38493669
[TBL] [Abstract][Full Text] [Related]
3. Early Effects of Intensive Lipid-Lowering Treatment on Plaque Characteristics Assessed by Virtual Histology Intravascular Ultrasound.
Lee JH; Shin DH; Kim BK; Ko YG; Choi D; Jang Y; Hong MK
Yonsei Med J; 2016 Sep; 57(5):1087-94. PubMed ID: 27401638
[TBL] [Abstract][Full Text] [Related]
4. Effect of alirocumab on coronary plaque in patients with coronary artery disease assessed by optical coherence tomography.
Gao F; Wang ZJ; Ma XT; Shen H; Yang LX; Zhou YJ
Lipids Health Dis; 2021 Sep; 20(1):106. PubMed ID: 34511134
[TBL] [Abstract][Full Text] [Related]
5. Impact of evolocumab on the pharmacodynamic profiles of clopidogrel in patients with atherosclerotic cardiovascular disease: a randomised, double-blind, placebo-controlled study.
Franchi F; Ortega-Paz L; Rollini F; Been L; Rivas A; Maaliki N; Zhou X; Pineda AM; Suryadevara S; Soffer D; Zenni M; Angiolillo DJ
EuroIntervention; 2023 Mar; 18(15):1254-1265. PubMed ID: 36602868
[TBL] [Abstract][Full Text] [Related]
6. Effects of alirocumab on endothelial function and coronary atherosclerosis in myocardial infarction: A PACMAN-AMI randomized clinical trial substudy.
Rexhaj E; Bär S; Soria R; Ueki Y; Häner JD; Otsuka T; Kavaliauskaite R; Siontis GC; Stortecky S; Shibutani H; Spirk D; Engstrøm T; Lang I; Morf L; Ambühl M; Windecker S; Losdat S; Koskinas KC; Räber L;
Atherosclerosis; 2024 May; 392():117504. PubMed ID: 38513436
[TBL] [Abstract][Full Text] [Related]
7. Impact of statin therapy on coronary plaque composition: a systematic review and meta-analysis of virtual histology intravascular ultrasound studies.
Banach M; Serban C; Sahebkar A; Mikhailidis DP; Ursoniu S; Ray KK; Rysz J; Toth PP; Muntner P; Mosteoru S; García-García HM; Hovingh GK; Kastelein JJ; Serruys PW;
BMC Med; 2015 Sep; 13():229. PubMed ID: 26385210
[TBL] [Abstract][Full Text] [Related]
8. Early differential changes in coronary plaque composition according to plaque stability following statin initiation in acute coronary syndrome: classification and analysis by intravascular ultrasound-virtual histology.
Hwang DS; Shin ES; Kim SJ; Lee JH; Kim JM; Lee SG
Yonsei Med J; 2013 Mar; 54(2):336-44. PubMed ID: 23364965
[TBL] [Abstract][Full Text] [Related]
9. Atherosclerotic plaque stabilization and regression: a review of clinical evidence.
Sarraju A; Nissen SE
Nat Rev Cardiol; 2024 Jul; 21(7):487-497. PubMed ID: 38177454
[TBL] [Abstract][Full Text] [Related]
10. Characteristics of Coronary Atherosclerosis Related to Plaque Burden Regression During Treatment With Alirocumab: The ARCHITECT Study.
Pérez de Isla L; Díaz-Díaz JL; Romero MJ; Muñiz-Grijalvo O; Mediavilla JD; Argüeso R; de Andrés R; Fuentes F; Sánchez Muñoz-Torrero JF; Rubio P; Álvarez-Baños P; Mañas D; Suárez Gutierrez L; Saltijeral Cerezo A; Mata P;
Circ Cardiovasc Imaging; 2024 Jan; 17(1):e016206. PubMed ID: 38205656
[TBL] [Abstract][Full Text] [Related]
11. Regression and Stabilization of Coronary Vulnerable Plaque by Evolocumab as Assessed by Multidetector Row Computed Tomography.
Shiga Y; Idemoto Y; Tashiro K; Imaizumi T; Ueda Y; Yano Y; Norimatsu K; Nakamura A; Miura SI
Intern Med; 2020 Oct; 59(19):2391-2395. PubMed ID: 32611955
[TBL] [Abstract][Full Text] [Related]
12. Hypercholesterolemia and in-vivo coronary plaque composition in patients with coronary artery disease: a virtual histology - intravascular ultrasound study.
Seo YH; Lee CS; Yuk HB; Yang DJ; Park HW; Kim KH; Kim WH; Kwon TG; Bae JH
Korean Circ J; 2013 Jan; 43(1):23-8. PubMed ID: 23408780
[TBL] [Abstract][Full Text] [Related]
13. Glucagon-like Peptide-1 analogues and delipidation of coronary atheroma in statin-treated type 2 diabetic patients with coronary artery disease: The prespecified sub-analysis of the OPTIMAL randomized clinical trial.
Kataoka Y; Kitahara S; Funabashi S; Makino H; Matsubara M; Matsuo M; Omura-Ohata Y; Koezuka R; Tochiya M; Tamanaha T; Tomita T; Honda-Kohmo K; Noguchi M; Murai K; Sawada K; Iwai T; Matama H; Honda S; Fujino M; Nakao K; Yoneda S; Takagi K; Otsuka F; Asaumi Y; Hosoda K; Nicholls SJ; Yasuda S; Noguchi T
Atheroscler Plus; 2024 Jun; 56():1-6. PubMed ID: 38617596
[TBL] [Abstract][Full Text] [Related]
14. Role of Lipid-Lowering and Anti-Inflammatory Therapies on Plaque Stabilization.
Bryniarski KL; den Dekker W; Legutko J; Gasior P; Tahon J; Diletti R; Wilschut JM; Nuis RJ; Daemen J; Kleczynski P; Van Mieghem NM; Jang IK
J Clin Med; 2024 May; 13(11):. PubMed ID: 38892807
[TBL] [Abstract][Full Text] [Related]
15. Atherosclerotic coronary plaque regression from lipid-lowering therapies: A meta-analysis and meta-regression.
Rivera FB; Cha SW; Varona MC; Fernandez Co EM; Magalong JV; Aparece JP; De Oliveira-Gomes D; Kaur G; Gulati M
Am J Prev Cardiol; 2024 Jun; 18():100645. PubMed ID: 38550634
[TBL] [Abstract][Full Text] [Related]
16. Evolocumab Treatment in Dyslipidemic Patients Undergoing Coronary Artery Bypass Grafting: One-Year Safety and Efficacy Results.
Nasso G; Vignaroli W; Amodeo V; Bartolomucci F; Larosa C; Contegiacomo G; Demola MA; Girasoli C; Valenzano A; Fiore F; Bonifazi R; Triggiani V; Vitobello V; Errico G; Lamanna A; Hila D; Loizzo T; Franchino R; Sechi S; Valenti G; Diaferia G; Brigiani MS; Arima S; Angelelli M; Curcio A; Greco F; Greco E; Speziale G; Santarpino G
J Clin Med; 2024 May; 13(10):. PubMed ID: 38792527
[No Abstract] [Full Text] [Related]
17. Correction to: Predicting Benefit From Evolocumab Therapy in Patients With Atherosclerotic Disease: Using a Genetic Risk Score.
Circulation; 2024 Jun; 149(24):e1414. PubMed ID: 38857334
[No Abstract] [Full Text] [Related]
18. Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome.
Schwartz GG; Steg PG; Szarek M; Bhatt DL; Bittner VA; Diaz R; Edelberg JM; Goodman SG; Hanotin C; Harrington RA; Jukema JW; Lecorps G; Mahaffey KW; Moryusef A; Pordy R; Quintero K; Roe MT; Sasiela WJ; Tamby JF; Tricoci P; White HD; Zeiher AM;
N Engl J Med; 2018 Nov; 379(22):2097-2107. PubMed ID: 30403574
[TBL] [Abstract][Full Text] [Related]
19. Design of the randomized, placebo-controlled evolocumab for early reduction of LDL-cholesterol levels in patients with acute coronary syndromes (EVOPACS) trial.
Koskinas KC; Windecker S; Buhayer A; Gencer B; Pedrazzini G; Mueller C; Cook S; Muller O; Matter CM; Räber L; Heg D; Mach F;
Clin Cardiol; 2018 Dec; 41(12):1513-1520. PubMed ID: 30421481
[TBL] [Abstract][Full Text] [Related]
20. Alirocumab Reduces Total Nonfatal Cardiovascular and Fatal Events: The ODYSSEY OUTCOMES Trial.
Szarek M; White HD; Schwartz GG; Alings M; Bhatt DL; Bittner VA; Chiang CE; Diaz R; Edelberg JM; Goodman SG; Hanotin C; Harrington RA; Jukema JW; Kimura T; Kiss RG; Lecorps G; Mahaffey KW; Moryusef A; Pordy R; Roe MT; Tricoci P; Xavier D; Zeiher AM; Steg PG;
J Am Coll Cardiol; 2019 Feb; 73(4):387-396. PubMed ID: 30428396
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
